Article | June 1, 2022

Step Up To GMP Manufacturing Or Outsource To A CDMO

Source: Cytiva
GettyImages-1346675584-team-lab-research-development

Whether you are developing a new monoclonal antibody (mAb), cell therapy, gene therapy, or large molecule biologic drug, the decision to tackle GMP manufacturing in house or work with a contract development and manufacturing organization (CDMO) represents a pivotal crossroads in your product’s journey to market.

In this article, learn about the key factors to help you determine which strategy best suits your process, product, and team.

While in-house manufacturing offers the appeal of having complete control over your product and can provide long-term cost benefits, some complexities still exist. Are you and your team ready to take on the demands of GMP compliance and regulatory approval? Explore some considerations and tips for succeeding in GMP manufacturing.

Whether in-house or with a CDMO, find the development strategy that fits your business and fosters the success of your product’s journey to the clinic.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: